Abu Dhabi-based G42 Healthcare has signed a letter of intent with AstraZeneca with the aim of expanding their collaboration into diagnostics and clinical research and providing access to treatments for patients in the United Arab Emirates (UAE) and beyond.
According to the Department of Health in Abu Dhabi, G42 Healthcare and AstraZeneca had already signed a declaration of collaboration in December 2021.
The new agreement expands the partnership to build local research capabilities, conduct clinical trials in the UAE, and localize oncology biomarker testing in UAE.
